Prescriber's Corner
Belinostat for Relapsed or Refractory Peripheral T-Cell Lymphoma
Katelyn Hood, PharmD, and Arpita Shah, PharmD
Nationwide Children's Hospital, Columbus, Ohio, and Georgia Regents Medical Center, The University of Georgia College of Pharmacy, Augusta, Georgia
Katelyn Hood, PharmD,
Nationwide Children's Hospital, 700 Children's Drive, Columbus, OH 43205.
E-mail: katelyn.hood@nationwidechildrens.org
Authors’ disclosures of potential conflicts of interest are found at the end of this article.
J Adv Pract Oncol 2016;7:209–218 |
doi: 10.6004/jadpro.2016.7.2.6 |
© 2016 Harborside Press®
ABSTRACT
The FDA approval of belinostat provides APs with an additional option for heavily pretreated patients with relapsed/refractory peripheral T-cell lymphoma who did not achieve a desirable response to traditional chemotherapy agents. Read about the drug’s mechanism of action, key trials leading to approval, potential adverse events, and important dosing and administration information.
For access to the full length article, please
sign in.
